Allucent
Allucent, formed in 2022, is a global clinical research organization specializing in complex development areas such as oncology, rare diseases, and cell and gene therapies. The company offers comprehensive clinical trial services, regulatory strategy, and data management across more than 60 countries.
Company History
Allucent was formed in the spring of 2022 through the merger of several high-performance companies serving small and mid-sized biotechs. Its origins trace back to CATO SMS, a result of the 2019 merger between Cato Research and SMS-oncology. SMS-oncology, founded in 2007, specialized in offering clinical trial services and strategic consulting for anticancer drug development. Previous mergers included CATO SMS's acquisition of Array Biostatistics and Nuventra Pharma Sciences. In early 2022, CATO SMS merged with Pharm-Olam, enhancing Allucent’s global clinical trial service offerings.
Global Clinical Trial Experience
Allucent has conducted clinical trials in more than 60 countries globally. The company has worked on over 700 trials, with a significant focus on oncology. Their comprehensive trial experience includes complex development areas such as rare and orphan indications, and cell and gene therapies. Allucent's strong preclinical capabilities include both in vitro and in vivo studies, supporting their extensive global footprint.
Services
Allucent offers a wide range of services tailored to small and mid-sized biotechs. These include regulatory strategy and product development, regulatory intelligence, therapeutic knowledge, global strategy, and submissions for IND and NDA. They also assist with orphan drug designation and pediatric investigation plans. Allucent provides data management and analysis to support decision-making and regulatory submissions, alongside clinical trial design and clinical pharmacology services, including PK/PD assessments, First-in-Human studies, and clinical trial simulation.
Specialized Areas of Focus
Allucent specializes in some of the most complex development areas within the biotech industry. These include oncology, rare diseases, orphan indications, and cell and gene therapies. Across these areas, they deliver a full range of services, from clinical trial design and management to regulatory strategy and preclinical studies. Their oncology expertise is particularly notable, with the majority of their 700+ global clinical trials focusing on this sector.
Global Footprint and Office Locations
Allucent maintains a significant global presence, with offices across North America, Europe, and the Middle East. This extensive footprint facilitates their ability to conduct clinical trials in more than 60 countries. The widespread reach ensures comprehensive support and accessibility for clients seeking to develop and market innovative therapeutic solutions worldwide.